For the treatment of pulmonary hypertension in the world there is also a medicine called Remodulin
(Treprostinil). It is a synthetic analogue of prostacyclin. Treprostinil is indicated for the treatment of pulmonary arterial hypertension (WHO group 1) to reduce the symptoms associated with physical exercise. It can be administered as a continuous subcutaneous infusion or continuous intravenous infusion.
Remodulin is a prescription drug designed for adults with PAH. Remodulin has been studied
primarily in patients with NYHA class II-IV functional symptoms. Remodulin is transmitted
continuously using a pump connected to a small tube that is placed under the skin (subcutaneously),
or inserted into the veins in the upper portion of the vessel (intravenous).

https://www.remodulin.com/